Age-related Difference in Susceptibility of Apc(Min/+) Mice Towards the Chemopreventive Efficacy of Dietary Aspirin and Curcumin

Overview

Journal Br J Cancer

Specialty Oncology

Date 2003 Jun 5

PMID 12778080

Citations 8

Authors

S Perkins

A R Clarke

W Steward

A Gescher

Affiliations

Soon will be listed here.

Abstract

The nonsteroidal anti-inflammatory drug aspirin and the spice curcumin retard adenoma formation when administered long-term to Apc(Min/+) mice, a model of human familial adenomatous polyposis coli. Both agents interfere with cyclooxygenase activity. When aspirin is administered to Apc(Min/+) mice only postweaning, but not before, it is inefficacious, while curcumin given postweaning is active. Here the hypothesis was tested that dietary aspirin (0.05%) or curcumin (0.2%) prevent or delay adenoma formation in offsprings when administered to Apc(Min/+) mothers and up to the end of weaning, but not afterwards. Whereas curcumin was without effect when administered in this way, aspirin reduced numbers of intestinal adenomas by 21%. When aspirin given up to the end of weaning was combined with curcumin administered from the end of weaning for the rest of the animals' lifetime, intestinal adenoma numbers were reduced by 38%. The combination was not superior to intervention postweaning with curcumin alone. These results show that aspirin exerts chemopreventive activity in the Apc(Min/+) mouse during tumour initiation/early promotion, while curcumin is efficacious when given at a later stage of carcinogenic progression. Thus, the results suggest that in this mouse model aspirin and curcumin act during different 'windows' of neoplastic development.

Citing Articles

Effects of dietary aspirin on high-LET radiation-induced prostaglandin E2 levels and gastrointestinal tumorigenesis in Apc mice.

Suman S, Kumar S, Moon B, Angdisen J, Kallakury B, Datta K Life Sci Space Res (Amst). 2021; 31:85-91.

PMID: 34689954 PMC: 9808916. DOI: 10.1016/j.lssr.2021.09.001.

Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis.

Rohwer N, Kuhl A, Ostermann A, Hartung N, Schebb N, Zopf D Cancer Med. 2020; 9(7):2535-2550.

PMID: 31994315 PMC: 7131863. DOI: 10.1002/cam4.2881.

Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus.

Chen J, Stark L Biomedicines. 2017; 5(3).

PMID: 28718829 PMC: 5618301. DOI: 10.3390/biomedicines5030043.

Mechanisms of colitis-accelerated colon carcinogenesis and its prevention with the combination of aspirin and curcumin: Transcriptomic analysis using RNA-seq.

Guo Y, Su Z, Zhang C, Gaspar J, Wang R, Hart R Biochem Pharmacol. 2017; 135():22-34.

PMID: 28267439 PMC: 5541256. DOI: 10.1016/j.bcp.2017.02.021.

Bcl-2 is a critical mediator of intestinal transformation.

van der Heijden M, Zimberlin C, Nicholson A, Colak S, Kemp R, Meijer S Nat Commun. 2016; 7:10916.

PMID: 26956214 PMC: 4786877. DOI: 10.1038/ncomms10916.

References

Kinzler K, Vogelstein B . Lessons from hereditary colorectal cancer. Cell. 1996; 87(2):159-70. DOI: 10.1016/s0092-8674(00)81333-1. View

Perkins S, Verschoyle R, Hill K, Parveen I, Threadgill M, Sharma R . Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev. 2002; 11(6):535-40. View

Boolbol S, Dannenberg A, Chadburn A, Martucci C, Guo X, Ramonetti J . Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996; 56(11):2556-60. View

Plummer S, Holloway K, Manson M, Munks R, Kaptein A, Farrow S . Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene. 1999; 18(44):6013-20. DOI: 10.1038/sj.onc.1202980. View

STRUMIA M, Sample A, Hart E . An improved micro hematocrit method. Am J Clin Pathol. 1954; 24(9):1016-24. DOI: 10.1093/ajcp/24.9.1016. View

Williamson S, Kartheuser A, Coaker J, Kooshkghazi M, Fodde R, Burn J . Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis. 1999; 20(5):805-10. DOI: 10.1093/carcin/20.5.805. View

Findlay J, DeAngelis R, Kearney M, Welch R, Findlay J . Analgesic drugs in breast milk and plasma. Clin Pharmacol Ther. 1981; 29(5):625-33. DOI: 10.1038/clpt.1981.87. View

Torrance C, Jackson P, Montgomery E, Kinzler K, Vogelstein B, Wissner A . Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 2000; 6(9):1024-8. DOI: 10.1038/79534. View

Chiu C, McEntee M, Whelan J . Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice. Prostaglandins Leukot Essent Fatty Acids. 2000; 62(5):269-75. DOI: 10.1054/plef.2000.0154. View

10.

Jacoby R, Seibert K, Cole C, Kelloff G, Lubet R . The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 2000; 60(18):5040-4. View

11.

Moser A, Pitot H, Dove W . A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 1990; 247(4940):322-4. DOI: 10.1126/science.2296722. View

12.

Jacoby R, Cole C, Tutsch K, Newton M, Kelloff G, Hawk E . Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 2000; 60(7):1864-70. View

13.

Reuter B, Zhang X, Miller M . Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis. BMC Cancer. 2002; 2:19. PMC: 122065. DOI: 10.1186/1471-2407-2-19. View

14.

Ireson C, Orr S, Jones D, Verschoyle R, Lim C, Luo J . Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001; 61(3):1058-64. View

15.

Luongo C, Moser A, Gledhill S, Dove W . Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res. 1994; 54(22):5947-52. View

16.

Mahmoud N, Carothers A, Grunberger D, Bilinski R, Churchill M, Martucci C . Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis. 2000; 21(5):921-7. DOI: 10.1093/carcin/21.5.921. View

17.

Vane J . Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971; 231(25):232-5. DOI: 10.1038/newbio231232a0. View

18.

Ritland S, Gendler S . Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis. 1999; 20(1):51-8. DOI: 10.1093/carcin/20.1.51. View

19.

Schoenfeld A, Bar Y, Merlob P, Ovadia Y . NSAIDs: maternal and fetal considerations. Am J Reprod Immunol. 1992; 28(3-4):141-7. DOI: 10.1111/j.1600-0897.1992.tb00777.x. View

20.

Barnes C, Lee M . Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology. 1998; 114(5):873-7. DOI: 10.1016/s0016-5085(98)70305-1. View